{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-284964","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2021-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.032928+00:00","generated_at":"2026-06-29T01:02:32.336069+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Alector appoints Elizabeth Garofalo, M.D. to Board of Directors","bullets":["Dr. Garofalo appointed as Class II director with term expiring at 2023 annual meeting; effective Sept. 23, 2021.","Over 25 years of neurology drug development experience; formerly SVP and Global Head of Clinical Development at Novartis.","Received initial option grant of 33,235 shares (four-year vest) and annual cash retainer of $40,000.","Currently serves on boards of Acadia Pharmaceuticals, Exicure Inc., and Xenon Pharmaceuticals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-284964","json":"https://secwatch.observer/filing/0001193125-21-284964.json","markdown":"https://secwatch.observer/filing/0001193125-21-284964.md","text":"https://secwatch.observer/filing/0001193125-21-284964.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000119312521284964/0001193125-21-284964-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000119312521284964/d234235d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:02:32.336069+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99cd687f8b","claim":"Elizabeth A. Garofalo was appointed as Class II director at Alector, Inc..","evidence_excerpt":"On September 23, 2021, Elizabeth A. Garofalo, M.D. was appointed to the Board of Directors (the “Board”) of Alector, Inc. (the “Company”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000119312521284964/0001193125-21-284964-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}